Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 11/20 | 0.49 |
| ▸ | ACACB | O00763 | 2/20 | 0.47 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LIPC | P11150 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9900213 | 0.93 | SCN10A (0.48) | SCN10AACACBMAPTCYP2C9CYP2C19 | |
| SCHEMBL9901042 | 0.92 | ACACB (0.46) | SCN10AACACBMAPTCYP2C9CYP2C19 | |
| SCHEMBL9900584 | 0.92 | SCN10A (0.50) | SCN10AACACBLIPGLIPCSCN9A | |
| SCHEMBL9901613 | 0.92 | SCN10A (0.44) | SCN10AACACBMAPTCYP2C9CYP2C19 | |
| SCHEMBL9900389 | 0.91 | ACACB (0.45) | SCN10AACACBMAPTCYP2C9CYP2C19 | |
| SCHEMBL9900320 | 0.91 | SCN10A (0.42) | SCN10AACACBMAPTCYP2C9CYP2C19 | |
| SCHEMBL9901202 | 0.90 | SCN10A (0.41) | SCN10AACACBMAPTCYP2C9CYP2C19 | |
| SCHEMBL9900687 | 0.90 | SCN9A (0.43) | MAPTCYP2C9CYP2C19SMN1; SMN2SCN9A | |
| SCHEMBL15294759 | 0.90 | SCN9A (0.41) | ACACBSCN9A | |
| SCHEMBL9905524 | 0.89 | SCN10A (0.44) | SCN10AACACBMAPTCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649061-B1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Rottapharm Biotech Srl (IT) | 2015-05-13 | — | — | EP | disclosed |
| EP-2649061-B1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Rottapharm Biotech Srl (IT) | 2015-05-13 | — | — | EP | disclosed |
| US-8828987-B2 | Pyridine amide derivatives as EP4 receptor antagonists | ROTTAPHARM BIOTECH S.R.L. (IT) | 2014-09-09 | — | — | US | disclosed |
| US-8828987-B2 | Pyridine amide derivatives as EP4 receptor antagonists | ROTTAPHARM BIOTECH S.R.L. (IT) | 2014-09-09 | — | — | US | disclosed |
| EP-2649061-A1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Rottapharm S.p.A. (IT) | 2013-10-16 | — | — | EP | disclosed |
| US-20130261100-A1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2013-10-03 | — | — | US | disclosed |
| US-20130261100-A1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2013-10-03 | — | — | US | disclosed |
| WO-2012076063-A1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM S.P.A. (IT) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012076063-A1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM S.P.A. (IT) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261100-A1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | PTGER4, PTGER1, CNR1 | SCN10A 453/4885ACACB 2610/4885LIPG 4136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.